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Objective: To assess the cross-sectional association of epicardial fat with insulin resistance, major
abdominal adipose depots, and cardiovascular disease (CVD) risk factors in obese pre-pubertal and early
pubertal children.
Methods: By using magnetic resonance imaging in 30 pre-pubertal and early pubertal patients [21 males,
Tanner Stage I-II, median age 11.2 (2.95) y, BMI z-score 2.56  0.11 SDS], visceral (VAT), subcutaneous
(SAT), epicardial adipose tissues (EAT) and hepatic fat fraction (HFF) were estimated. Lipid proﬁle, liver
function tests, circulating adipokines and markers of inﬂammation [leptin, adiponectin, tumor necrosis
factors-alpha (TNF-alpha), C-reactive protein (CRP), interleukins 6 and 10 (IL-6, IL-10)] were assayed.
Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR).
Body composition was measured by dual-energy X-ray absorptiometry.
Results: In 14 insulin resistant children (HOMA-IR >2.5), median values of EAT were signiﬁcantly higher
than in insulin sensitive mates [54.0 (35.45) cm3 vs. 27.2 (17.03) cm3; p ¼ 0.03]. Moreover, EAT performed
no differently in identifying insulin resistant patients (AUC 0.737; 95% CI 0.538e0.936; p ¼ 0.028) from
VAT (AUC 0.772; 95% CI 0.599e0.945; p ¼ 0.011); SAT (AUC 0.795; 95% CI 0.628e0.0.962; p ¼ 0.006); and
HFF (AUC 0.777; 95% CI 0.607e0.947; p ¼ 0.010). Stepwise regression analysis showed that EAT
(b ¼ 0.025; 95% CI 0.012e0.038, p ¼ 0.001) and CRP (b ¼ 0.622; 95% CI 0.069e0.238, p ¼ 0.002) predicted
HOMA-IR (R2 ¼ 0.71; p ¼ 0.001), while VAT, SAT and HFF were excluded from the model.
Conclusions: In pre-pubertal and early pubertal obese children, EAT is a signiﬁcant marker of increased
insulin resistance and associated cardiovascular risk.
 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The epicardial adipose tissue (EAT) is a part of the visceral fat
deposited within the pericardic sac around the heart, between the
visceral layers of the pericardium and the outer wall of the
myocardium. EAT shares a common embryological origin with the
intra-abdominal visceral adipose tissue (VAT) and, as such, it is
a metabolically active adipose tissue [1]. Hence, although EATetry; CRP, C-reactive protein;
odel assessment of insulin
AT, epicardial adipose tissue;
s adipose tissue; TNF-alpha,
sue.
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nd Ltd. All rights reserved.represents only 1% of the total body fat mass in physiological
conditions, it may be particularly important in the pathophysiology
of the cardiovascular disease (CVD) risk associated with obesity [1].
The pericardial fat is usually referred to as the fat which is anterior
to the epicardial one and, therefore, located between the visceral
and parietal pericardium. However, not all experts adopt the same
nomenclature [2].
Owing to its close proximity to the heart and coronary vascu-
lature, the epicardial fat can secrete large amounts of pro-
inﬂammatory adipokines and free fatty acids which locally may
promote CVD [1]. In particular, perivascular adipose tissue
surrounding the coronary arteries may cause in situ vascular
dysfunction [3,4] and favor coronary atherosclerosis [5e7]. A
signiﬁcant relationship between epicardial fat volume and pres-
ence of coronary atherosclerosis measured by multislice computed
tomography has been reported in both subjects with asymptomatic
coronary artery disease [5] andwith type 2 diabetes [6]. A thickness
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predict the presence of signiﬁcant CAD in asymptomatic patients
[7]; while a cut-off EAT volume of 75 ml show 72% sensitivity and
70% speciﬁcity for detecting the presence of atherosclerosis [5].
Thickness and volumes of either epicardial or pericardial
adipose tissues close to the heart have been found quantitatively
associated with various CVD risk factors and particularly with waist
circumference and visceral fat as estimated also by magnetic
resonance imaging (MRI) [8]. Nevertheless, in most of the studies,
the association of either epicardial or pericardial fat with CVD risk
factors resulted independent of the amount of visceral fat [2e16]. In
the Framingham Heart Study, the fat volume within the pericar-
dium and the intra-thoracic fat volume (the whole fat within the
thorax minus the formed depot) correlated with coronary and
aortic calcium, respectively [2] and with multiple markers of
inﬂammation and oxidative stress [14]. Other studies showed that
pericardial fat volume [16e18], area [12,13], and thickness [8,10,19e
21] measured by computerized tomography scan [18,19], MRI
[12,13,17], echocardiography [8,19e22], and at autopsy [16] corre-
late with blood pressure [8,12,13], coronary artery calcium [5e7,10],
insulin resistance [13,20], early left ventricular dysfunction [20]
and left mass [16,23].
The few studies, performed in children, have investigated
ultrasonographically thickness of the subepicardial adipose tissue
[15,23]. Abaci et al. [15] provided normative values of subepicardial
fat thickness in 30 normal weight children and found increased
thickness in 46 obese age-matched patients. Albeit no signiﬁcant
correlation was found between epicardial adipose thickness and
degree of insulin resistance, a cut-off point of 4.1 mm identiﬁed
insulin resistant children [deﬁned as pre-pubertal children having
a value of Homeostasis Model Assessment of Insulin Resistance
(HOMA-IR) >2.5 and as pubertal ones with HOMA-IR >4] with 90%
sensitivity and 61% speciﬁcity. More recently, Mazur et al. [23]
failed to ﬁnd in 52 enrolled children any relationship between
increased EAT thickness and either insulin resistance or metabolic
syndrome after correction for waist circumference.
No study has hitherto investigated the association between EAT
and VAT, both estimated by an accurate technique, their interplay in
relation to insulin resistance, metabolic abnormalities and other
major abdominal adipose tissues (i.e., the Subcutaneous Adipose
Tissue, SAT; and the Hepatic Fat Fraction, HFF) in obese pre-
pubertal and early pubertal children.
Aim of the present study was to evaluate in obese pre-pubertal
and early pubertal children, cross-sectional associations of volumes
of epicardial adipose tissue as estimated by short-axis slice MRI
with insulin resistance estimated by the HOMA-IR, cardiovascular
risk factors and fat accumulation within the major abdominal fat
reservoirs.
2. Materials and methods
Thirty consecutive Caucasian obese pre-pubertal and early
pubertal children were recruited at the Obesity and Nutrition
Outpatient Clinic of the Pediatric Section of the University Hospital
of Verona.
Inclusion criteria were: no previous treatment for obesity,
Tanner stage I-II, no systemic, genetic, and endocrine disease, and
no use of medication. Puberty development was clinically assessed
on the basis of secondary sex characteristics. Tanner stages for
pubic hair, breast conﬁguration, and genital status were used as
reference [24].
The study protocol included estimation of anthropometrics,
body composition by Dual X-ray Energy Absorptiometry (DXA),
localized adiposity by MRI (1.5-T Avanto, Siemens, Erlangen,
Germany), estimation of fasting glucose, insulin, lipid proﬁle,alanine aminotransferase (ALT), aspartate aminotransferase (AST),
g-glutamyl-transferase (g-GT), adipokines (leptin, adiponectin) and
circulating markers of inﬂammation (C-reactive protein, CRP;
Tumor Necrosis Factor-a, TNF-a; Interleukin-6 and 10, IL-6 and IL-
10). HOMA-IR was computed as: fasting plasma glucose  fasting
insulin/22.5, with glucose and insulin expressed in mmol l1 and
mUI ml1 [25].
Oral glucose tolerance test was performed in all children and
impaired glucose tolerance or type 2 diabetes was diagnosed
according to the criteria of the American Diabetes Association [26].
The protocol was in accordance with the 1975 Declaration of
Helsinki, and its revision in 1983, and was approved by the Ethical
Committee of the University Hospital of Verona. Informed consent
was obtained from the patients’ parents or responsible guardians.
2.1. Anthropometrics and body composition estimation
Height was measured to the nearest 0.5 cm on a standardized
height board. Weight was determined to the nearest 0.1 kg on
a standard physician’s beam scale, with the subject dressed only in
light clothes and without shoes. BMI was calculated as weight
(kilograms) divided by height (meters) squared. Body composition
was assessed by using a DPX-L densitometer (Lunar Corp., Madison,
WI). The subjects were scanned in light clothing while lying ﬂat on
their backs. On the day of each test, the DPX-L was calibrated
according to the manufacturer’s instructions. The percent body fat
mass (FM%) was calculated as (total body fat/body weight)  100,
where body fat and weight are expressed in kilograms.
2.2. Case deﬁnition
Overweight was deﬁned as a BMI  85th (1.036 SDS) and <95th
(1.645 SDS) percentiles; obesity as a BMI  95th percentile (1.645
SDS) for age and sex [27]. Hyper-triglyceridemia was deﬁned as
fasting triglycerides 150 mg/dl; low HDL-cholesterol as fasting
HDL <40 mg/dl [28].
Systolic (SBP) and diastolic blood pressure (DBP) weremeasured
three times while the subjects were seated, and the measurements
were averaged for the analysis. Hypertensionwas deﬁned as a value
of systolic blood pressure 130 mm Hg or diastolic blood pressure
85 mm Hg [28].
Insulin resistance was deﬁned as a HOMA-IR 2.5 [29].
2.3. Laboratory assessment
Fasting glucose concentration, lipids, and liver enzymes were
measured by standard in-house methods. Plasma insulin levels
were measured by chemiluminescent immunometric assays (Euro/
DPC Ltd, Llanberis, UK). Plasma adiponectin was measured by
enzyme-linked immunosorbent assay (ELISA, B-Bridge Interna-
tional, Mountain View, CA) according to the manufacturer’s
instructions. LDL-cholesterol level was estimated by the Friedewald
formula [30]. Plasma CRP and leptin were both assessed by ELISA
(DBC, London, Ontario, Canada). Plasma adiponectin was measured
by ELISA (B-Bridge International, Mountain View, CA). IL-6, IL-10,
and TNF-a were measured by a multiplex sandwich ELISA (Pierce
Biotechnology, Rockford, IL). The reported limits of detection of
these assays were 0.01 mg/l, 0.5 ng/ml, 0.23 mg/ml, 0.2 pg/ml,
0.2 pg/ml, and 0.8 pg/ml for highly sensitive CRP, leptin, adipo-
nectin, IL-6, IL-10, and TNF-a, respectively.
2.4. Acquisition of MRI imagines
Measurement of abdominal fat distribution and HFF was per-
formed as elsewhere described [31]. A single slice at the L4 level
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compartment is bounded by the internal margin of the abdominal
muscle walls and includes intraperitoneal, preperitoneal, and
retroperitoneal adipose tissues. The SAT compartment includes the
adipose tissues outside the VAT boundary. With the use of a cursor,
a free-hand region of interest (ROI) was drawn around deep SAT
(DSAT) and superﬁcial SAT (SSAT). The mean signal
intensity  standard deviation of the adipose tissue was obtained
from these ROI. Hepatic fat accumulation was measured using MRI
along with the Dixon method [32]. A hepatic fat fraction cut-off of
5.5% was chosen as the threshold to diagnose steatosis [33].
For the EAT assessment, we used a dark blood prepared T1-
weighted multislice turbo spin-echo pulse sequence with a water
suppression prepulse to obtain a transversal four-chamber view
and short-axis images in the same orientations used for the cine
short-axis images. Imaging parameters were as follows: time of
repetition ¼ 800 ms, time to echo ¼ 24 ms, slice thickness ¼ 4 mm,
interslice gap ¼ 2 mm, and ﬁeld of view ¼ 30e34 cm. The EAT
amount was calculated by using the modiﬁed Simpson’s rule with
integration over the image slices. Epicardial fat was deﬁned as the
fat between the myocardial border and the internal visceral layer of
the pericardium. The border between epicardial and pericardial fat
was localized by visual inspection of the entire cine series in all
slices. EAT areas were then traced manually on consecutive end-
systolic short-axis images beginning at the mitral valve and
ending at the last slice containing cardiac adipose tissue. The areas
obtained for each slice were added together and multiplied by slice
thickness to yield the volume. EAT mass was obtained by multi-
plying epicardial fat volumes by fat density (0.9196 g ml1).
2.5. Statistical analysis
Continuous data are reported as median and Interquartile Range
(IQR), unless otherwise indicated,with categorical data as counts and
percentages. The one-way analysis of variance and the Manne
Whitney U test were used for inter-group comparisons as appro-
priate. Thenonparametric Spearmancorrelationcoefﬁcientwasused.
Backward linear regression analyses were performed to identify
independent correlates of HOMA-IR. The parameters successively
considered were estimates of fat distribution (EAT, VAT, SAT and
HFF) and, successively, markers of inﬂammation. The signiﬁcant
model which explained the largest variability of HOMA-IR was
reported as the best model. Receiver operating characteristic curveTable 1
Anthropometrics, metabolic proﬁle and insulin resistance in the sample as a whole and
Range (IQR). P refers to statistical signiﬁcance at the ANOVA. Alanine Aminotransferase
Resistance, HOMA-IR.
Whole sample (N ¼ 30) I tertile
Age (years) 11.2 (2.91) 11.7 (
Body weight (kg) 65.5 (26.4) 57.4 (
Height (cm) 150 (19) 144 (
BMI (kg/m2) 28 (6.9) 27.5 (
BMI z-score (SDS) 2.6 (0.83) 2.30 (
Waist circumference (cm) 85 (15) 81 (
SBP (mm/hg) 119 (13.5) 110 (
DBP (mm/hg) 70 (18) 65 (
Fasting glucose (mg/dl) 84 (7) 83.5 (
Fasting insulin (mUI/ml) 11.6 (9.9) 10.6 (
HOMA-IR 2.41 (2.04) 2.18 (
Cholesterol (mg/dl) 174 (31.7) 156.5 (
HDL-cholesterol (mg/dl) 44.5 (13) 46.5 (
LDL-cholesterol (mg/dl) 109 (19.4) 94.5 (
Triglycerides (mg/dl) 99 (41) 80.5 (
ALT (mUI/ml) 29 (10) 37.5 (
AST(mUI/ml) 31 (7) 28 (
g-GT (mUI/ml) 16 (10) 14.5 (
Bold represents statistically signiﬁcant.analysis was used to evaluate speciﬁcity and sensitivity of estimates
of abdominal and epicardial adiposity to identify insulin resistant
children (HOMA-IR >2.5).
The p value was set as statistically signiﬁcant at p < 0.05. Data
analysis was performed by using SPSS statistical software (SPSS
V12.0, Inc., Chicago, IL).
3. Results
Table 1 summarizes anthropometric and metabolic parameters
in the sample population as a whole, as well as stratiﬁed by tertiles
of epicardial fat.
Table 2 reports data on total body and abdominal adiposity,
adipokines and inﬂammatory molecules in the same groups.
Patients in the highest tertile of EAT had higher body weight
(p ¼ 0.002), absolute amount of body fat mass (p ¼ 0.01), BMI
(p ¼ 0.007), and subcutaneous adipose tissue (p ¼ 0.03) than
children in the lowest tertiles.
When patients from the ﬁrst and the second tertiles were
combined and compared to the ones in the highest tertile, the latter
showed also signiﬁcantly higher waist circumference (p ¼ 0.02),
VAT (p ¼ 0.05), diastolic blood pressure (p ¼ 0.04), and g-GT
(p ¼ 0.04).
Sex distribution was not different among EAT tertiles (p ¼ 0.2).
In the whole sample, gender differences were observed just in
leptin concentration [males vs. females: 26.9 (15.13) vs. 70.51 (68.9)
ng/ml; p ¼ 0.001].
3.1. Insulin resistance and metabolic syndrome
In the fourteen children (46%) classiﬁed as having insulin
resistance, EAT median values were signiﬁcantly higher [54.0
(35.45) cm3] than in insulin sensitive mates [27.2 (17.03) cm3;
p ¼ 0.03]. No difference was observed between the ones having
[N ¼ 15, 50%; EAT ¼ 48.2 (37.2) cm3] or the ones with not hepatic
steatosis [EAT ¼ 37.3 (31.2) cm3; p ¼ 0.3].
The distribution of metabolic abnormalities clustering into the
metabolic syndrome was signiﬁcantly different between sexes
and among tertiles of epicardial fat: 12 boys presented with 1
abnormality and 4 with two; 7 girls presented with simple obesity,
2 with one abnormality, none of them with 2 or more abnormal-
ities (p ¼ 0.02). Two boys resulted intolerant at the glucose
tolerance test. EAT median values were signiﬁcantly higher in thedivided into tertiles of epicardial fat. Data are reported as median and Interquartile
; ALT, Aspartate Aminotransferase, AST; Homeostasis Model Assessment of Insulin
II tertile III tertile p
4.7) 10.9 (2.4) 11.5 (2.35) 0.4
24.5) 58.1 (30.7) 78.8 (23.3) 0.02
29.5) 149.5 (27) 151.5 (11.5) 0.4
5.2) 27.4 (5.8) 34 (7.8) 0.007
0.85) 2.62 (0.7) 2.94 (0.7) 0.2
13) 82 (17.2) 91 (16) 0.07
15.5) 118.5 (14) 120 (11.7) 0.2
14) 68.5 (16.5) 78.5 (25.5) 0.1
9.25) 85.9 (7.50) 84.5 (11.25) 0.7
11.7) 11 (10.9) 15.6 (13.2) 0.3
2.41) 2.4 (1.98) 3.35 (2.6) 0.2
55) 176 (35.25) 178.5 (22) 0.6
10) 46 (16.25) 42.5 (12.25) 0.9
43.5) 108.3 (16.6) 111.5 (22.05) 0.5
51.5) 77 (52.5) 105 (44.75) 0.7
4.50) 31.5 (10.5) 30.5 (6.75) 0.6
30.5) 29.5 (27.5) 25.5 (16.75) 0.9
3.25) 16 (17.25) 26 (5.75) 0.09
Table 2
Total body, abdominal, epicardial adiposity and inﬂammatory proﬁle in the sample as a whole and divided into tertiles of epicardial fat. Data are reported as median and
Interquartile Range (IQR). P refers to statistical signiﬁcance at the ANOVA.C-Reactive Protein, CRP; Tumor Necrosis Factor-alpha, TNF-alpha; Interleukin-6 and 10, IL-6, IL-10.
Whole sample (N ¼ 30) I tertile II tertile III tertile p
Fat free mass (kg) 38.6 (15.9) 34.6 (12.3) 34.2 (17.7) 46.1 (12.8) 0.06
Fat mass (kg) 25.7 (11.4) 22.4 (10) 23.3 (17.7) 30.7 (11.5) 0.01
Fat mass (%) 40 (7.3) 40 (7.4) 39.3 (10.6) 43.3 (5.8) 0.3
Epicardial fat (cm3) 38.8 (37.0) 18.4 (9.0) 38.8 (16.2) 64.6 (26.5) <0.0001
Visceral fat (cm2) 68.2 (41.6) 57.6 (37.3) 59.3 (45.5) 82.8 (31.8) 0.1
Subcutaneous fat (cm2) 165.4 (70.5) 151.7 (32.7) 155.1 (53.1) 219.0 (102.7) 0.03
Hepatic fat fraction (%) 4.9 (21.0) 3.4 (10.7) 3.9 (27.6) 9.08 (38.5) 0.4
Leptin (ng/ml) 33.2 (17.4) 30.08 (29.5) 35.5 (30.2) 34.2 (71.5) 0.7
Adiponectin (mg/ml) 7.9 (4.3) 6.5 (3.2) 10.01 (6.9) 8.99 (3.82) 0.4
CRP (mg/l) 2.9 (5.97) 4.53 (7.14) 2.9 (4.2) 2.4 (7.7) 0.7
TNF-alpha (pg/ml) 0.4 (2.7) 0.35 (2.91) 1.8 (6.5) 0.35 (3.2) 0.3
IL-6 (pg/ml) 3.9 (6.0) 3.6 (3.97) 8.7 (14.9) 3.9 (5.10) 0.4
IL-10 (pg/ml) 0.3 (0.9) 0.3 (0.3) 1.2 (3.9) 0.3 (0.7) 0.2
Bold represents statistically signiﬁcant values.
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with simple obesity or complicated by only one abnormality
(p ¼ 0.014).3.2. Correlation and linear regression analyses
In Fig. 1, linear regressions between volumes of EAT and visceral
(Panel A, R2 ¼ 0.202; p ¼ 0.01), subcutaneous (Panel B, R2 ¼ 0.242;Fig. 1. Linear regressions between epicardial adipose tissue (EAT) and visceral fat area (VAT
Panel B; R2 ¼ 0.2418; p ¼ 0.006; y ¼ 1.4692 x þ 125.36), hepatic fat fraction (HFF; Panel C
p ¼ 0.002; y ¼ 0.0309 x þ 1.3338).p ¼ 0.006), hepatic fat fraction (Panel C, R2 ¼ 0.137; p ¼ 0.04) and
HOMA-IR (Panel D, R2 ¼ 0.285; p ¼ 0.002) were plotted.
At the Spearman correlation analysis, signiﬁcant relationships
were observed between EAT and body weight (ro ¼ 0.553,
p ¼ 0.002); kg of fat mass (ro ¼ 0.563, p ¼ 0.001); waist circum-
ference (ro ¼ 0.473, p ¼ 0.008); visceral (ro ¼ 0.405, p ¼ 0.03) and
subcutaneous adipose tissue (ro ¼ 0.545, p ¼ 0.002); HOMA-IR
(ro ¼ 0.420, p ¼ 0.02); systolic blood pressure (ro ¼ 0.414,
p ¼ 0.03) and g-GT (ro ¼ 0.776, p ¼ 0.003).; Panel A; R2 ¼ 0.2018; p ¼ 0.013; y ¼ 0.4656 x þ 46.727); subcutaneous fat area (SAT,
; R2 ¼ 0.1371; p ¼ 0.04; y ¼ 0.2976 x þ 1.5043) and HOMA-IR (Panel D; R2 ¼ 0.2852;
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p ¼ 0.006); LDL-cholesterol (ro ¼ 0.453, p ¼ 0.014); and CRP
(ro ¼ 0.724, p ¼ 0.001).
SAT was correlated with body weight (ro ¼ 0.702, p < 0.0001);
BMI (ro ¼ 0.840, p < 0.0001); BMI z-score (ro ¼ 0.642, p < 0.0001);
body fat mass (ro ¼ 0.724, p < 0.0001) and fat mass % (ro ¼ 0.433,
p ¼ 0.017), HFF (ro ¼ 0.586, p ¼ 0.001); HDL-cholesterol
(ro ¼ 0.391, p ¼ 0.03); ALT (ro ¼ 0.502, p ¼ 0.008) and adipo-
nectin (ro ¼ 0.456, p ¼ 0.01).
HFF correlated with BMI (ro ¼ 0.518, p ¼ 0.003); BMI z-score
(ro ¼ 0.466, p ¼ 0.009); waist circumference (ro ¼ 0.511, p ¼ 0.004);
levels of ALT (ro ¼ 0.612, p ¼ 0.002), AST (ro ¼ 0.611, p ¼ 0.001),
adiponectin (ro ¼ 0.426, p ¼ 0.019); and HOMA-IR (ro ¼ 0.413,
p ¼ 0.023).
3.3. MRI adiposity, low-grade inﬂammation and prediction of
insulin resistance
Insulin resistant patients were identiﬁed at the ROC analysis by
EAT (AUC 0.737; 95% CI 0.538e0.936; p ¼ 0.03); VAT (AUC 0.772;
95% CI 0.599e0.945; p ¼ 0.011); SAT (AUC 0.795; 95% CI 0.628e
0.0.962; p ¼ 0.006); and HFF (AUC 0.777; 95% CI 0.607e0.947;
p ¼ 0.010).
Since EAT correlated signiﬁcantly with both VAT and SAT, and
SAT with HFF, we run stepwise regression models to identify
predictors of HOMA-IR among the above mentioned fat depots and
adipokines measured in the present series. The model which pre-
dicted HOMA-IR in the best possible way? (R2 ¼ 0.71; p ¼ 0.001)
included epicardial fat (b ¼ 0.025, 95% CI 0.012e0.038, p ¼ 0.001)
and CRP (b ¼ 0.154, 95% CI 0.069e0.238, p ¼ 0.002) as predictors,
while the other variables were excluded.
4. Discussion
To the best of our knowledge, this is the ﬁrst report focusing on
cross-sectional associations of epicardial fat with metabolically
active abdominal fat depots as measured by MRI, insulin resistance
and markers of inﬂammation in pre-pubertal and early pubertal
obese children. Themain ﬁndings of the present investigation are: i)
the amount of epicardial fat is highly correlated with visceral and
subcutaneous fat (Fig. 1); ii) insulin resistant obese children have
higher volumes of epicardial fat than insulin sensitive children, and
EATexplains 45% of the variance in insulin resistance when coupled
with CRP as marker of low-grade inﬂammation; iii) EAT performs
not differently from VAT, SAT and HFF in identifying patients with
insulin resistance.
Taken together, these ﬁndings would suggest that ectopic fat
accumulates simultaneously at several sites and systemic insulin
resistance may promote such accumulation.
Data from the present series conﬁrm the association between
EAT and overall general adiposity already described in adult [8,11,12]
and pediatric samples [15,23] but, for the ﬁrst time in a pediatric
population, present also ﬁndings supporting the signiﬁcant associ-
ation of EAT with visceral fat as estimated by MRI. Mazur et al. [23]
evaluated epicardial fat thickness by ultrasonography and found
a signiﬁcant association between EAT and waist circumference.
Hence, the authors suggested the routine ultrasound measurement
of EAT as clinical means to estimate the CVD risk associated with
increased visceral adiposity, as previously proposed for adults [8].
In the present series, we took advantage by a high reliable
technique, the MRI, for the simultaneous measurements of EAT
volume, VAT, SATandHFF to verifywhether EATbehaves as amarker
of insulin resistance not different fromVAT inpre-pubertal children.
The association of EAT with SAT is also noteworthy. It has been
suggested that the relationship between epicardic and pericardicfat is similar to that between SAT and VAT. As fat accumulation
within the different abdominal compartments is related to
a different adipocyte size and adipogenic capacity of these tissues
during adolescence, a time when the expansion of white adipose
tissue results from combined adipocyte hypertrophy and hyper-
plasia [34], epicardic and pericardic fat may behavior similarly and
the epicardial fat expansibility may parallel the SAT expansibility.
As to EAT ability to predict insulin resistance, we did not observe
a signiﬁcant correlation between EAT and HOMA-IR, but insulin
resistant patients had signiﬁcantly higher EAT than insulin sensi-
tive mates. In keeping with such ﬁndings, Abaci’s et al. [15] found
no association between epicardial thickness and insulin resistance,
but EAT was able to identify insulin resistant patients with good
speciﬁcity and sensitivity.
To dissect the impact of epicardial fat on insulin resistance
despite the cross-sectional design of the present study and over-
come the co-linearity expected among estimates of abdominal
adiposity, a backward regression approach was used. The results of
this analysis showed that EAT was able to explain 45% of the vari-
ance in insulin resistance when coupled with CRP. The circulating
protein is a marker of inﬂammation, whose levels have been found
to be independent of insulin resistance in young patients [35]. In
our series, EAT did not correlate with any marker of inﬂammation.
Hence, epicardial fat may play a role in the pathogenesis of
cardiovascular risk associated with obesity but, at least in very
young patients, this role is not pivotal and may require external
insults promoting local inﬂammation which develops later than
insulin resistance. Insulin resistance itself and free fatty acid turn-
over, aging, smoking endotoxin may be nominees as insults
[36,37]. In the Framingham study, signiﬁcant correlations were
observed between epicardial fat and markers of inﬂammation (i.e.,
CRP, IL-6) also after adjusting for the degree of adiposity [14].
It is quite intriguing the strong association between EAT and g-
GT (r0 ¼ 0.884), a robust marker of metabolic risk in healthy indi-
viduals [38] which, so far, has been found limited to patients with
coronary artery diseases? [39].
Serum levels of adiponectinwere found to be inversely correlated
with the thickness of the subcutaneous fat. This observation is
consistent with previous reports in pre-pubertal children [40,41]. In
the latter, very similar levels of adiponectin protein concentrations
have been found in adipocytes from paired SAT and VAT, suggesting
either that the differences observed in adiponectin expression in
adults are not translated intodifferences inproteinproductionor that
they develop later in life. Alternatively, large variations in total adi-
ponectin between the two fat compartments may only be observed
after the development of an abnormal body composition with an
increasedproportionof visceral fat. Interestingly, in fat samples taken
fromnormalweight children, thosewithhigherBMI SDS, evenwithin
the non-obese range, had lower levels of adiponectin in both SATand
VAT adipocytes compared with leaner individuals, and this negative
correlation was statistically signiﬁcant in the SAT adipocytes. Hence,
this suggests that increasing BMI, SDS in childhood is associatedwith
reductions in SAT adiponectin content [41].
We are aware of some limitations of the study. Mainly, our cross-
sectional study cannot determine, by design, causal relationships but
just describe associations and that are limited to obese patients.
Virtually, by having added normal weight control children, some
associations (i.e., between epicardial fat and markers of inﬂamma-
tion) might become evident. However, as no direct beneﬁt from
participating in the study could be envisaged for normal weight
children, the Ethical Committee denied approval to enclose normal
weight children as controls for the study. Moreover, we did not
estimate the intra-thoracic fat, and, therefore, we could not confute
the hypothesis that the intra-thoracic fat is more predictive of CVD
risk, inﬂammation and insulin resistance than the epicardial fat [42].
M. Manco et al. / Atherosclerosis 226 (2013) 490e495 495The strength of the study relies upon the simultaneous
measurements of regional adiposity by MRI and the speciﬁc age
range of the children. In fact, the pre-pubertal age and the
successive transition to the puberty identify critical time-windows
when the child’s body starts to accumulate adiposity. Following the
path of associations between the different fat depots (i.e., SAT vs.
VAT) may allow tracking the natural history of the CVD risk asso-
ciated with obesity in childhood.
In conclusion, epicardial fat is positively and highly correlated
with increased total body adiposity and, in particular, with
abdominal fat accumulation in pre-pubertal and early pubertal
obese children. Fat accumulation at the epicardial site is higher in
insulin resistant pre-pubertal and early pubertal children.
Longitudinal studies, aimed at investigating the interplay
between adiposity make-up and macrophage inﬁltration of the
different fat compartments, are warranted for tracking the natural
history of CVD in young patients.Disclosure declaration
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